Pulse Biosciences (NASDAQ:PLSE) Sees Strong Trading Volume After Insider Buying Activity

Pulse Biosciences, Inc. (NASDAQ:PLSE) saw unusually-strong trading volume on Wednesday after an insider bought additional shares in the company. Approximately 113,639 shares were traded during mid-day trading, a decline of 37% from the previous session’s volume of 179,575 shares.The stock last traded at $10.39 and had previously closed at $9.73.

Specifically, CEO Burke Thomas Barrett acquired 10,000 shares of Pulse Biosciences stock in a transaction that occurred on Monday, May 20th. The stock was purchased at an average price of $8.56 per share, with a total value of $85,600.00. Following the completion of the transaction, the chief executive officer now owns 10,000 shares in the company, valued at $85,600. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 71.50% of the company’s stock.

Pulse Biosciences Price Performance

The company has a fifty day simple moving average of $8.05 and a two-hundred day simple moving average of $8.69. The company has a market capitalization of $659.88 million, a P/E ratio of -14.75 and a beta of 1.73.

Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings data on Thursday, March 28th. The company reported ($0.21) EPS for the quarter.

Hedge Funds Weigh In On Pulse Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD acquired a new stake in Pulse Biosciences during the first quarter valued at approximately $88,000. Vanguard Group Inc. boosted its holdings in Pulse Biosciences by 28.8% during the first quarter. Vanguard Group Inc. now owns 847,212 shares of the company’s stock valued at $7,379,000 after purchasing an additional 189,227 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in Pulse Biosciences by 63.6% during the first quarter. BNP Paribas Financial Markets now owns 7,597 shares of the company’s stock valued at $66,000 after purchasing an additional 2,952 shares in the last quarter. Inspire Investing LLC boosted its holdings in Pulse Biosciences by 32.1% during the first quarter. Inspire Investing LLC now owns 41,358 shares of the company’s stock valued at $360,000 after purchasing an additional 10,039 shares in the last quarter. Finally, PNC Financial Services Group Inc. acquired a new stake in Pulse Biosciences during the fourth quarter valued at approximately $242,000. 76.95% of the stock is currently owned by institutional investors.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.